LivaNova to Present Updates on Autonomic Regulation Therapy at the 23rd Annual Scientific Meeting of the Heart Failure Society of America
Autonomic Regulation Therapy (ART) is a novel neuromodulation approach to treating heart failure (HF), and the implantable LivaNova VITARIA® System delivers ART using Vagus Nerve Stimulation (VNS) to treat patients with chronic, symptomatic HF with reduced ejection fraction (HFrEF). The VITARIA System is currently being used to study the effects of ART in a prospective, international, randomized, controlled clinical trial (ANTHEM-HFrEF Pivotal Study). Dr.
“Automatic Regulation Therapy may be a breakthrough treatment option for patients with advanced, chronic heart failure, and we have applied the findings from previous ART research to the ANTHEM-HFrEF Pivotal Study. This therapy holds promise and is based on a contemporary understanding of the underlying neuroscience,” said Dr. Anand. “The more we evaluate the effects of this treatment for heart failure patients, the more we can learn about the disease and the potential ability of ART to transform patient lives.”
The VITARIA System received CE Mark approval in 2015 and is being evaluated under the
“Heart failure continues to be a large unmet need, and
Additionally, two ART posters will be presented during the HFSA meeting. Posters are on display
“Vagus Nerve Stimulation for Chronic Heart Failure: Differences in Therapy Delivery and Clinical Efficacy in ANTHEM-HF, INOVATE-HF, and NECTAR-HF”
“Long-Term Performance of Vagus Nerve Stimulation Lead: Low Rate of Complications and Failures”
To learn more about the LivaNova VITARIASystem and the treatment of heart failure with ART, visit www.ARTforHeartFailure.com.
For more information, please visit www.livanova.com.
Safe Harbor Statement
This press release contains “forward-looking statements” concerning our goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding ART and our approach to treating heart failure by delivering ART using VNS. Actual results may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of our Annual Report on Form 10-K for the year ended
Deanna Wilke, +1 (281) 727-2764
Director, Corporate Communications